MedTrace Logo

Investigation of Efficacy of Improved Acetaminophen Labeling

NCT01592448 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 662

Last updated 2014-11-18

No results posted yet for this study

Summary

The purpose of this study is to evaluate, through brief, one-on-one cognitive interviews, the efficacy of 'enhanced' acetaminophen messages and icons in improving consumer understanding and use of prescription (Rx) and non-prescription (over-the-counter, OTC) acetaminophen containing products compared to the current standard.

Conditions

  • Acetaminophen Overdose
  • Pain

Interventions

BEHAVIORAL

Active Ingredient Icon

Enhanced bottles will have a symbol, or icon, designed to draw attention to active ingredient information. The icon is a black hexagon containing two letters denoting the active ingredient of the medication (i.e. "Ac" for acetaminophen). Over-the-counter bottles will have the icon placed on the front of the bottle next to active ingredient information and on the back of the bottle in the drug facts to the left of the active ingredient information. Prescription bottles will have the icon placed below the directions for how to take the medication and will be accompanied by a brief statement indicating the medicine contains acetaminophen.

Sponsors & Collaborators

  • Emory University

    collaborator OTHER

  • McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

    collaborator INDUSTRY

  • Northwestern University

    lead OTHER

Principal Investigators

  • Michael S. Wolf, PhD, MPH · Northwestern University

  • Ruth M. Parker, MD · Emory University

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-10-31
Primary Completion
2013-03-31
Completion
2013-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01592448 on ClinicalTrials.gov